photo of the Declerck-Allegaert family

Declerck-Allegaert Family: From Family Laboratory to an Empire Worth Over 37 Million Euros

The Declerck-Allegaert family, founders of Klinisch Laboratorium Declerck, have transformed a local business into a major player in healthcare services in Flanders. With advanced technologies and rapid medical results, this laboratory gained notoriety, culminating in its acquisition by Australian giant Sonic Healthcare in 2015. Today, with assets of over 37 million euros, the family continues to stand out for its commitment to the community and quality of care.

photo by Louis Ide

Louis Ide: From Medicine to Politics, a Fortune of 8 Million Euros in the Service of Belgium

Louis Ide, Belgian doctor and politician, embodies the alliance between medical expertise and political commitment. An influential member of the N-VA, he made a name for himself as a senator while pursuing a career in tropical medicine and clinical biology. With a fortune estimated at over 8 million euros, Louis Ide continues to play a key role in legislative debates and actively contributes to public health and Belgian society. Find out how this man of many talents balances his political, medical and family responsibilities.

The 3 Janssen heirs of the UCB management family

The Janssen Family Dynasty: Secular Influence and a 3-Billion-Euro Fortune

The Janssen family, one of Belgium's most influential dynasties, has positioned itself at the heart of the banking, industrial and pharmaceutical sectors. With assets estimated at over 3 billion euros, their legacy is marked by strategic alliances, notably with the Solvay group and UCB, and by rigorous management of their assets. From Daniel Janssen to Charles-Antoine Janssen, each generation has strengthened the family's grip on the Belgian economy. Discover how this family has combined tradition, innovation and strategy to become one of Belgium's wealthiest.

photo by Dr. Paul Janssen

Dr. Paul Janssen: The Visionary Entrepreneur Behind a 300 Million Euro Fortune and a Pharmaceutical Legacy

Dr. Paul Janssen, founder of Janssen Pharmaceutica, is one of the most influential figures in the Belgian pharmaceutical industry. With a legacy estimated at over 300 million euros, Janssen revolutionized medicine with innovative medicines, while remaining a central figure in the company after its takeover by Johnson & Johnson. In addition to his medical contributions, he left a significant cultural imprint, with a unique collection of pre-Columbian art. Discover how this visionary built a pharmaceutical empire while influencing Belgian art and economics.

woman of color analyzing the Medina laboratory of Famille De Raedt-Verheyden

De Raedt-Verheyden family: Colossal 1.7-billion-euro empire in biotechnology

Gino De Raedt and Frederica Verheyden have built a financial empire estimated at over 1.7 billion euros, from a simple medical laboratory in 1978 to major players in European biotechnology. Their journey, marked by strategic acquisitions and a spectacular merger with Biogroup, illustrates an exceptional entrepreneurial vision. With record dividends and diversified investments in real estate and private equity, the De Raedt-Verheyden couple have become one of Belgium's largest fortunes, while preparing for the future with their daughter Ann. Their story embodies the perfect blend of scientific innovation and financial genius.

Rest home designed by Frank Bamelis and Bart Vanderschrick

Frank Bamelis and Bart Vanderschrick: The 41-Million-Euro Titanic Empire in Senior Care

Frank Bamelis and Bart Vanderschrick, founders of Senior Assist in 2006, have built an empire in the elderly care sector, valued at over 41 million euros. Their company manages 32 residential care centers and 147 assisted living facilities in Belgium, accommodating nearly 2,800 residents and employing 1,800 people. Despite international expansion and service diversification, Senior Assist encountered financial difficulties in 2017, leading to the sale of certain assets. The company, structured with a plurality of shareholders and present in Luxembourg, illustrates the challenges and opportunities of the senior care sector, which is constantly evolving to meet the needs of an aging population.